Netherlands · Delayed Price · Currency is EUR Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of EUR 964.00 million. The enterprise value is 910.07 million.
| Market Cap | 964.00M |
| Enterprise Value | 910.07M |
Important Dates
The last earnings date was Thursday, March 12, 2026.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 685.15 million shares outstanding. The number of shares has increased by 6.17% in one year.
| Current Share Class | 685.15M |
| Shares Outstanding | 685.15M |
| Shares Change (YoY) | +6.17% |
| Shares Change (QoQ) | +50.75% |
| Owned by Insiders (%) | 3.08% |
| Owned by Institutions (%) | 20.86% |
| Float | 664.08M |
Valuation Ratios
The trailing PE ratio is 397.00 and the forward PE ratio is 53.01.
| PE Ratio | 397.00 |
| Forward PE | 53.01 |
| PS Ratio | 3.01 |
| PB Ratio | 4.08 |
| P/TBV Ratio | 8.00 |
| P/FCF Ratio | 20.98 |
| P/OCF Ratio | 20.69 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.24, with an EV/FCF ratio of 19.80.
| EV / Earnings | 374.79 |
| EV / Sales | 2.84 |
| EV / EBITDA | 24.24 |
| EV / EBIT | 32.51 |
| EV / FCF | 19.80 |
Financial Position
The company has a current ratio of 2.59, with a Debt / Equity ratio of 0.42.
| Current Ratio | 2.59 |
| Quick Ratio | 2.02 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 2.66 |
| Debt / FCF | 2.15 |
| Interest Coverage | 1.78 |
Financial Efficiency
Return on equity (ROE) is 1.02% and return on invested capital (ROIC) is 2.87%.
| Return on Equity (ROE) | 1.02% |
| Return on Assets (ROA) | 4.48% |
| Return on Invested Capital (ROIC) | 2.87% |
| Return on Capital Employed (ROCE) | 8.39% |
| Weighted Average Cost of Capital (WACC) | 4.93% |
| Revenue Per Employee | 792,954 |
| Profits Per Employee | 6,010 |
| Employee Count | 404 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 0.75 |
Taxes
In the past 12 months, Pharming Group has paid 8.78 million in taxes.
| Income Tax | 8.78M |
| Effective Tax Rate | 80.25% |
Stock Price Statistics
The stock price has increased by +69.88% in the last 52 weeks. The beta is 0.16, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | +69.88% |
| 50-Day Moving Average | 1.43 |
| 200-Day Moving Average | 1.26 |
| Relative Strength Index (RSI) | 50.45 |
| Average Volume (20 Days) | 9,814,929 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharming Group had revenue of EUR 320.35 million and earned 2.43 million in profits. Earnings per share was 0.00.
| Revenue | 320.35M |
| Gross Profit | 281.60M |
| Operating Income | 27.46M |
| Pretax Income | 10.94M |
| Net Income | 2.43M |
| EBITDA | 37.01M |
| EBIT | 27.46M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
The company has 152.54 million in cash and 98.61 million in debt, with a net cash position of 53.93 million or 0.08 per share.
| Cash & Cash Equivalents | 152.54M |
| Total Debt | 98.61M |
| Net Cash | 53.93M |
| Net Cash Per Share | 0.08 |
| Equity (Book Value) | 236.01M |
| Book Value Per Share | 0.36 |
| Working Capital | 156.44M |
Cash Flow
In the last 12 months, operating cash flow was 46.59 million and capital expenditures -637,923, giving a free cash flow of 45.96 million.
| Operating Cash Flow | 46.59M |
| Capital Expenditures | -637,923 |
| Depreciation & Amortization | 9.73M |
| Net Borrowing | -3.68M |
| Free Cash Flow | 45.96M |
| FCF Per Share | 0.07 |
Margins
Gross margin is 87.90%, with operating and profit margins of 8.57% and 0.76%.
| Gross Margin | 87.90% |
| Operating Margin | 8.57% |
| Pretax Margin | 3.42% |
| Profit Margin | 0.76% |
| EBITDA Margin | 11.55% |
| EBIT Margin | 8.57% |
| FCF Margin | 14.35% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.17% |
| Shareholder Yield | -6.17% |
| Earnings Yield | 0.25% |
| FCF Yield | 4.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.
| Last Split Date | Mar 5, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Pharming Group has an Altman Z-Score of 2.8 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.8 |
| Piotroski F-Score | 5 |